These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16426329)

  • 21. Conversion to sirolimus in solid organ transplantation: a single-center experience.
    Egidi MF; Cowan PA; Naseer A; Gaber AO
    Transplant Proc; 2003 May; 35(3 Suppl):131S-137S. PubMed ID: 12742485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De novo thrombotic microangiopathy in two kidney transplant recipients from the same deceased donor: A case series.
    Roberts D; Siegman I; Andeen N; Woodland D; Deloughery T; Rueda J; Olyaei A; Rehman S; Norman D; Lockridge J
    Clin Transplant; 2020 Jul; 34(7):e13885. PubMed ID: 32314417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
    Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G
    J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation.
    Furmańczyk A; Komuda-Leszek E; Durlik M
    Ann Transplant; 2009; 14(4):47-51. PubMed ID: 20009155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A calcineurin antagonist-free induction/maintenance strategy for immunosuppression in elderly recipients of renal allografts from elderly cadaver donors: long-term results from a prospective single centre trial.
    Arbogast H; Hückelheim H; Schneeberger H; Illner WD; Tarabichi A; Fertmann J; Wimmer CD; Hillebrand GF; Mistry-Burchardi N; Thomae R; Acikgöz A; Land W
    Clin Transplant; 2005 Jun; 19(3):309-15. PubMed ID: 15877790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of mycophenolate mofetil and calcineurin inhibitor as maintenance immunosuppression for kidney transplant recipients: A meta-analysis of randomized controlled trials.
    Deng J; Lu Y; He L; Ou J; Xie H
    Turk J Med Sci; 2021 Jun; 51(3):1080-1091. PubMed ID: 33356028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
    Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up of 100 high-risk renal transplant recipients converted from calcineurin inhibitors to sirolimus: a single center experience.
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Tawab KA; Balaha MA; Abraham M; Said T; Nair MP; Al-Waheeb S; Al-Muzairai I; Nampoory MR
    Transplant Proc; 2009 Jun; 41(5):1666-70. PubMed ID: 19545704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
    Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
    Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrence of hemolytic-uremic syndrome in renal transplant recipients: a meta-analysis.
    Ducloux D; Rebibou JM; Semhoun-Ducloux S; Jamali M; Fournier V; Bresson-Vautrin C; Chalopin JM
    Transplantation; 1998 May; 65(10):1405-7. PubMed ID: 9625029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical profile and outcomes of
    Saikumar Doradla LP; Lal H; Kaul A; Bhaduaria D; Jain M; Prasad N; Thammishetti V; Gupta A; Patel M; Sharma RK
    Saudi J Kidney Dis Transpl; 2020; 31(1):160-168. PubMed ID: 32129209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Early conversion from calcineurin inhibitor to sirolimusto after renal transplantation:a prospective, open-label and non-randomized control study].
    Huang H; Xie W; Wu J; Xu Y; Yu X; Ren P; Chen J
    Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(42):3293-7. PubMed ID: 25622626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcineurin inhibitor-free immunosuppressive strategy in elderly recipients of renal allografts from deceased donors: 1-year results from a prospective single center trial.
    Arbogast HP; Hoffmann JN; Illner WD; Hillebrand GF; Fischereder M; Jauch KW; Land W
    Transplant Proc; 2009; 41(6):2529-32. PubMed ID: 19715968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.